What are the postremission treatment recommendations for better-risk patients with acute myeloid leukemia (AML)?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

Cytogenetics [inv(16) or t(16;16), t(8;21)] and molecular abnormalities (normal cytogenetics: with NPM 1 mutation or isolated CEBPA mutation in the absence of FLT3-ITD):

  • High-dose cytarabine 3 g/m2 IV over 3h every 12h on days 1, 3, and 5 for four cycles [6] or

  • High-dose cytarabine 3 g/m2 IV over 3h every 12h on days 1, 3, and 5 for two cycles plus  autologous stem cell transplantation [6]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!